Rgenix Stock

rgenix.comHealthcareFounded: 2010Funding to Date: $83.5MM

Rgenix is a developer of first-in-class drugs that target key pathways in cancer progression.

Register for Details

For more details on financing and valuation for Rgenix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Rgenix.

Register Today

Team

Management Team

Robert Wasserman MD
Chief Medical Officer
David Darst
Chief Operating Officer & Board Observer
Masoud Tavazoie Ph.D
Co-Founder, Board Member and Chief Executive Officer
Roger Waltzman MD
Chief Medical Officer
Sohail Tavazoie Ph.D
Co-Founder, Scientific & Clinical Advisor
Eric Rowinsky MD
Board Member & President

Board Members

David Darst
Noam Ohana
Conegliano Ventures
Saeed Tavazoie Ph.D
Eric Rowinsky MD
Nilesh Kumar Ph.D
Novo Holdings
Antoine Papiernik
Sofinnova Partners
Masoud Tavazoie Ph.D
Nancy Chang Ph.D
Peter Van Vlasselaer Ph.D

Other companies like Rgenix in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$4.26B

News

Rgenix, Inc. announced today that industry veteran Robert Wasserman, MD, has joined the Rgenix management team as its new Chief Medical Officer.
Rgenix announces $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs.